Vaxcyte/$PCVX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Ticker
- $PCVX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 507
- Headquarters
- San Carlos, United States
- Website
- vaxcyte.com
Vaxcyte Metrics
BasicAdvanced
$9.8B
-
-$7.65
1.21
-
Price and volume
Market cap
$9.8B
Beta
1.21
52-week high
$90.75
52-week low
$39.87
Average daily volume
3.2M
Financial strength
Current ratio
5.724
Quick ratio
5.481
Long term debt to equity
0.039
Total debt to equity
0.042
Profitability
EBITDA (TTM)
-1,148.78
Management effectiveness
Return on assets (TTM)
-22.61%
Return on equity (TTM)
-36.51%
Valuation
Price to book
3.26
Price to tangible book (TTM)
3.26
Price to free cash flow (TTM)
-9.372
Free cash flow yield (TTM)
-10.67%
Free cash flow per share (TTM)
-6.619
Growth
Earnings per share change (TTM)
85.35%
3-year earnings per share growth (CAGR)
32.95%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Analyst projections of the future price of Vaxcyte stock.
Bulls say / Bears say
VAX-31 cleared OPUS-1’s prespecified primary immunogenicity endpoints, matching licensed vaccines on shared serotypes and showing a similar safety profile. This is a strong first pivotal result for the adult programme. (Vaxcyte)
Its 31-serotype design could offer broader coverage than the current 20- and 21-valent adult vaccines. In OPUS-1, VAX-31 also showed superiority for three serotypes unique to the candidate, which may help it stand out if approved. (BioPharma Dive, Vaxcyte)
Vaxcyte has completed enrolment in all three adult Phase 3 trials, with results from OPUS-2 and OPUS-3 expected in the first half of 2027. Those readouts, alongside infant-study results, provide a series of near-term catalysts for the programme. (Vaxcyte)
In the individual comparison with Merck’s Capvaxive, VAX-31 missed the more stringent non-inferiority threshold for two of 19 shared serotypes, although both met the historical threshold. This leaves a potential point of concern in direct comparisons with a marketed rival. (Vaxcyte, BioPharma Dive)
OPUS-1 is only part of the evidence package: the company still needs OPUS-2 and OPUS-3 results and a manufacturing consistency study before its planned BLA filing in the first half of 2028. Delays or weaker findings could push back the regulatory and launch timetable. (Vaxcyte)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Vaxcyte News
AllArticlesVideos
Funds containing Vaxcyte
AllUSDEURGBP
Fund name | Fund size | $PCVX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.59% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.59% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.29% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.29% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.